Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Suter, T. M.
Right arrow Articles by Meier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suter, T. M.
Right arrow Articles by Meier, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:647-649, 2002
© 2002 European Society for Medical Oncology

Editorial

Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?

T. M. Suter and B. Meier

Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland

Cardiac contractile dysfunction is the most serious cardiotoxic effect of anthracycline therapy and a major limitation for the use of this effective antineoplastic treatment. The reported incidence of doxorubicin-induced cardiac dysfunction varies from 4%, at a cumulative dose of 500–550 mg/m2, to >36% in patients receiving 600 mg/m2 or more [1]. Interestingly, there is a non-linear correlation between the incidence of contractile dysfunction and the cumulative dose of anthracyclines, and toxicity varies significantly among different anthracyclines.

The prognosis of anthracycline-induced cardiotoxicity is poor, and possibly even worse than those of ischemic or idiopathic dilated cardiomyopathies [2]. In untreated patients, mortality from anthracycline-induced cardiomyopathy is as high as 40% over 5 years. However, recent data suggest that medical therapy may improve the prognosis of patients dramatically. Furthermore, the onset of anthracycline-induced heart failure can occur years after . . . [Full Text of this Article]

Acknowledgements

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. J. Barrett-Lee, J. M. Dixon, C. Farrell, A. Jones, R. Leonard, N. Murray, C. Palmieri, C. J. Plummer, A. Stanley, and M. W. Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Ann. Onc., May 1, 2009; 20(5): 816 - 827.
[Abstract] [Full Text] [PDF]